Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -60K | -57K | 0 | 0 |
| Operating Income | -31.5B | -36M | -43M | -42M | -21M |
| EBITDA | -30M | -34M | -40M | -41M | -21M |
| Net Income | -37M | -38M | -43M | -41M | -17M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.894
+2.29% today
1Y Change
-35.09%
Window
Jun 26, 2025 → Jun 22, 2026
Coverage: 247 bars · Jun 26, 2025 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PDS Biotechnology Corporation (PDSB) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $0.89 and down 35.1% across the available one-year price window (Jun 26, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +28.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +28.2%, free cash flow -79057.5% with operating margin 0.0% and ROIC -0.6%. Stock Foundry combines PDSB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
PDSB
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
PDSB Max Drawdown
-62.97%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PDSB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$16.9M
+58.6% YoY
Free Cash Flow
-$12.5M
+51.4% YoY
Revenue Growth
+0.0%
EPS Growth
+28.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -60K | -57K | 0 | 0 |
| Operating Income | -31.5B | -36M | -43M | -42M | -21M |
| EBITDA | -30M | -34M | -40M | -41M | -21M |
| Net Income | -37M | -38M | -43M | -41M | -17M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 27M | 42M | 57M | 74M | 65M |
| Total Assets | 30M | 45M | 59M | 77M | 67M |
| Total Liabilities | 21M | 26M | 33M | 33M | 4M |
| Shareholder Equity | 9M | 19M | 26M | 44M | 63M |
| Total Debt | 5.2B | 22M | 24M | 23M | 490K |
| Net Debt | 5.2B | -20M | -33M | -50M | -65M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12M
+51.4% YoY
Capital Expenditures
0
Free Cash Flow
12M
+51.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-242.0%
Debt / Equity
561.21x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.